The AFBRECANE study, part of the Human Heredity and Health in Africa (H3Africa) initiative, investigates the genomics and epidemiology of breast cancer and its molecular subtypes in Nigerian women. Since 2018, the study has recruited and assessed over 600 women aged 18 years and older with a clinical and histological diagnosis of breast cancer from Ibadan, Enugu and Abuja in Nigeria, with the goal of recruiting 1,000 women. Control participants include 11,000 women with no history of cancer at recruitment who are participants of the African Collaborative Center for Microbiome and Genomics Research (ACCME) cohort study. Breast cancer cases are followed up at regular clinic appointments. Cancer registry and ACCME data are also recorded.
Study design
Cohort - clinical, Cohort
Number of participants at first data collection
635 (AFBRECANE participants)
~11,000 (ACCME/control participants)
Recruitment is ongoing
Age at first data collection
≥ 18 years (AFBRECANE participants)
≥ 18 years (ACCME/control participants)
Participant year of birth
Varied (AFBRECANE participants)
Varied (ACCME/control participants)
Participant sex
Female
Representative sample at baseline?
No
Sample features
Country
Year of first data collection
2018
Primary Institutions
National Institutes of Health (NIH) (Government, United States of America)
University of Maryland, College Park (UMD) (Academic, United States of America)
University of Nigeria Teaching Hospital (Academic, Nigeria)
Profile paper DOI
Funders
National Cancer Institute (NCI) (Government, United States of America)
National Human Genome Research Institute (NHGRI) (Government, United States of America)
National Institutes of Health (NIH) (Government, United States of America)
Office of Research on Women’s Health (ORWH) (Government, United States of America)
Office of the Director (OD) (Government, United States of America)
Ongoing?
Yes
Data types collected

Engagement
Keywords
Consortia and dataset groups